13 results about "Enterovirus" patented technology

An in vitro approach for detecting Enterovirus-D68 (EV-D68) is disclosed. In one aspect, two or more EV-D68 genomic regions are amplified with primers that each include a 5' universal tail and an EV-D68-specific sequence (SEQ ID NOs: 47-92). The tails enable indexing and sequencing of tiled amplicons to confirm EV-D68 presence and permit lineage or subclade assignment. In another aspect, a type-specific RT-qPCR assay employs a forward primer (SEQ ID NO: 95), a reverse primer (SEQ ID NO: 96), and a fluorescent probe (SEQ ID NO:97) for rapid detection. Primer sets and kits comprising the primers, probe, and optional reagents are provided for environmental, clinical, or research testing performed outside the body, including wastewater-based surveillance. The universal tails are selected to avoid sequence overlap with any target amplicon. The methods, uses, and kits support sensitive EV-D68 detection across circulating variants and facilitate scalable sequencing and public-health monitoring.

The application discloses application of sulforaphane in preparation of an antienterovirus drug and belongs to the technical field of medicines, wherein the sulforaphane can inhibit the expression of viral proteins, inhibit viral genome replication and inhibit the production of virus particles to achieve the purpose of resisting enteroviruses; specifically, the sulforaphane can inhibit the replication of enteroviruses by up-regulating the content of p53 proteins. In addition, the sulforaphane can also be used for reducing the cell morphological damage caused by enteroviruses.

This invention discloses a traditional Chinese medicine composition for assisting in the improvement of hand-foot-mouth disease in infants and young children, belonging to the field of traditional Chinese medicine technology. The composition consists of eight medicinal herbs: lotus leaf, coix seed, angelica dahurica, kudzu root, platycodon root, agastache rugosa, cimicifuga rhizome, and dandelion, with a defined optimal medicinal ratio. Based on the seasonal differences in the pathogenesis of hand-foot-mouth disease, this invention targets the core pathologies of winter (cold congestion of microvessels, water and sodium retention, and internal heat generation) and spring and summer (hypothalamic sympathetic activation, increased heart rate, and visceral heat overload). It also addresses the technical deficiencies of clinical Western medicine, cold-natured traditional Chinese medicine, calamine lotion, and diuretics, such as vasoconstriction, kidney damage, central nervous system disorders, increased skin exudation, and rebound water retention. This invention employs a combination of warming and cooling herbs, regulating the ascending and descending functions, and promoting diuresis and protecting the body's vital energy. The synergistic effects of these herbs can dilate spasmodic microvessels, improve renal perfusion, stabilize abnormal heart rates, stabilize the hypothalamic center, and assist in antagonizing enteroviruses. By targeting and reducing abnormal permeability of skin capillaries with Angelica dahurica and Platycodon grandiflorus, it reduces blood extravasation and inhibits the formation and exudation of herpes from the root cause. This invention has mild medicinal properties, is suitable for all seasons, and has high safety. It can effectively improve symptoms of hand-foot-mouth disease such as fever, herpes, irritability, and cold extremities, reduce the risk of severe illness, antagonize the toxic side effects of commonly used clinical drugs, and is suitable for the delicate constitution of infants and young children, possessing good prospects for clinical application and promotion.

The present invention relates to a bifunctional peptide comprising a virus-binding portion (2) and a mucin-binding portion (1) covalently linked to the virus-binding portion (2). The virus-binding portion is selected from peptides that bind to SARS-CoV-2, influenza A virus, influenza B virus, rhinovirus and other enteroviruses, human parainfluenza virus, and / or metapneuvirus. The mucin-binding portion is selected from lectins such as trefoil factor 3.

The application discloses a virus marker for depression diagnosis and a screening method and application thereof, relates to the technical field of biological detection, and the virus marker for depression diagnosis comprises at least one of s_Stenotrophomonas_virus_Pokken, g_Pokkenvirus, s_Dickeya_virus_AD1 and g_Alexandravirus. The application firstly takes the enterovirus group characteristics as the biomarker of depression, breaks through the limitation that traditional mental illness diagnosis relies on subjective scale evaluation; compared with the prior art, the four virus markers can be used for the diagnosis of clinical depression alone or in combination, have the characteristics of non-invasiveness and high sensitivity, can effectively distinguish the depression patients from the healthy people, can early discover the high-risk groups, and provide a new objective diagnosis method for the precise typing of depression.

The application provides a broad-spectrum monoclonal antibody of enterovirus A population and application thereof, and belongs to the technical field of molecular biology and immune analysis. The monoclonal antibody comprises the following six CDR regions: the amino acid sequences of the CDR regions of the heavy chain are respectively shown in SEQ ID No. 1-SEQ ID No. 3; and the amino acid sequences of the CDR regions of the light chain are respectively shown in SEQ ID No. 4-SEQ ID No. 6. The application also provides a nucleotide fragment encoding the monoclonal antibody, a recombinant vector and an engineering cell line comprising the nucleotide fragment, an antibody conjugate and their uses. The monoclonal antibody is a non-neutralizing antibody of IgG1 subtype, can be combined with enterovirus A population viruses in a broad spectrum, and can be used for preparing a reagent or / and a kit for detecting enterovirus A population viruses, and for preparing a medicine for inhibiting, preventing or / and treating enterovirus A population viruses.

The application discloses a method for GI and GII type norovirus on-site typing detection, comprising the following steps: in the presence of primers, carrying out double RT-RPA reaction on a template, then adding the amplification product after reaction into a CRISPR / Cas12a detection system of GI and GII type norovirus respectively, carrying out fluorescence analysis, and completing GI and GII type norovirus on-site typing detection. The application covers each subtype of norovirus GI and GII, has no cross reaction with common gastroenteritis viruses such as rotavirus and enterovirus, can effectively distinguish the two genotypes of GI and GII, and has no off-target phenomenon, and the minimum detection limit of the application for the GI and GII genotype norovirus is 10 2 copies / µL and 1 copies / µL respectively. The whole detection process can be completed within 35 min under the condition of 37 DEG C constant temperature, can be directly used for on-site detection by means of an ultraviolet flashlight, and does not need laboratory instruments and professional operation.

Compounds, methods, and compositions for treating or preventing viral infections using nucleoside compounds. The nucleoside compounds have increased antiviral activity potential with the result of inhibiting at least one of flaviviruses, herpesviruses, polyomaviruses, alphaviruses, enteroviruses, filoviruses matonaviruses, phenuiviruses, Hepatitis B virus, and / or coronaviruses.

The present application belongs to the technical field of biological medicine, and particularly relates to a kind of short peptide and application in enterovirus inhibiting product.The short peptide provided by the present application has the amino acid sequence as shown in SEQ ID NO.1;Or the short peptide has the partial segment of the amino acid sequence as shown in SEQ ID NO.1.The short peptide of the present application has significant advantages in anti-enterovirus spectrum and inhibiting efficiency.It has strong inhibiting effect on enterovirus group A (such as CV-A6, CV-A10), enterovirus group B (such as CV-B3, CV-A9, ECHO 11) and enterovirus group C (such as PV-1).It has no obvious cytotoxicity.The short peptide provided by the present application makes up the defect of narrow virus spectrum of lactoferrin in the prior art, and has good clinical application value.

This invention discloses a liquid-phase probe-targeted capture library construction method and kit for enteroviruses, belonging to the field of virus detection technology. This invention combines targeted enrichment with high-throughput sequencing, featuring broad coverage, high flexibility, high sensitivity, and high specificity, enabling multi-dimensional information output including quantitative, qualitative, and in-depth analysis. Through the probe-targeted capture "enrichment-screening" mechanism, this invention reduces probe redundancy design, minimizes background nucleic acid interference from intestinal flora, exhibits excellent adaptability to complex samples, and eliminates the need for complex sample pretreatment, making it suitable for large-scale epidemiological detection.

The application discloses primer probe composition, kit, method and use for enterovirus universal type and EV71, CA6, CA10, CA16 detection, which comprises the combination of upstream primers, probes and downstream primers for CA16, CA6, CA10, EVA71 and enterovirus universal type detection respectively. The application realizes the typing detection of enterovirus universal type and EV71, CA16, CA6, CA10 in one tube by designing specific probes and primers and combining qPCR+melt curve technology, and the system is provided with an internal standard, so that the extraction and amplification process can be monitored.

This invention particularly provides compounds, pharmaceutical compositions, and methods related to the treatment of viral infections caused by coronaviruses or enteroviruses. The invention provides compounds of formulas (I), (II), and (III) and methods for using said compounds in a therapeutic manner. These compounds are peptide mimics of the coronavirus protease 3CL and are suitable for treating conditions caused by viral infections, including COVID-19.